News
** U.S.-listed shares of biotech co jump 19.8% to $8.35 premarket - among most heavily traded stocks across U.S. exchanges ** A patient with COVID-19 complications in the U.S. treated with co's PLX cell therapy for the first time [nGNX8KlZD9] ** Last week, the treatment was tested in 3 medical centers in Israel, resulting in 100% survival rate for all 7 patients who were suffering from acute respiratory failure and inflammatory complications [nL4N2BV3HJ] ** Co intends to start a multinational clinical trial as soon as possible for PLX cells in the treatment of patients suffering from complications associated with COVID-19 ** Separately, BioCryst Pharmaceuticals begun enrollment to its early-stage clinical trial testing co's antiviral drug galidesivir in patients with COVID-19 [nGNX1LM4DC] ** Cell therapy developer Athersys got FDA nod to start a mid-to-late stage trial of its cell therapy in patients with severe acute respiratory distress syndrome caused by COVID-19 [nL3N2C11UR] ** Diagnostics company Biocept Inc also to begin physician-ordered testing requests for its molecular diagnostic test for COVID-19 from April 15 [nL3N2C11VF] ** Israeli biotechnology company Can-Fite BioPharma receives regulatory clearance on Monday to commence clinical trial of its drug candidate Piclidenoson to treat moderate-to-severe symptoms in COVID-19 infected patients ** Shares of BCRX, ATHX, BIOC and CANF were up between 25% and 59% premarket (Reporting by Trisha Roy in Bengaluru) ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;))
